Table 5.
Total number of major adverse coronary events (MACEs) and adverse cardiac and vascular events (ACVEs) in 6.4 ± 5.6 (range, 1–27) years before and 6.8 ± 4.9 (range, 1–23) years after commencing chronic lipoprotein apheresis (LA)
| All patients (n = 118) | |||
|---|---|---|---|
| Before LA (n) | During LA (n) | Reduction rate (%) | |
| MACE | 261 | 53 | 79.7 (p < 0.0001) |
| Myocardial infarction | 68 | 10 | 85.3 (p < 0.0001) |
| Percutaneous coronary intervention | 138 | 37 | 73.2 (p < 0.0001) |
| Coronary artery bypass graft | 55 | 6 | 89.1 (p < 0.0001) |
| ACVE | 289 | 77 | 73.3 (p < 0.0001) |
| Patients with severe hypercholesterolemia (n = 83) | |||
| MACE | 167 | 44 | 73.7 (p < 0.0001) |
| Myocardial infarction | 48 | 8 | 83.3 (p < 0.0001) |
| Percutaneous coronary intervention | 81 | 31 | 61.7 (p < 0.0001) |
| Coronary artery bypass graft | 38 | 5 | 86.8 (p < 0.0001) |
| ACVE | 184 | 66 | 64.1 (p < 0.0001) |
| Patients with isolated Lp(a) elevation (n = 35) | |||
| MACE | 94 | 9 | 90.4 (p < 0.0001) |
| Myocardial infarction | 20 | 2 | 90.0 (p < 0.0001) |
| Percutaneous coronary intervention | 57 | 6 | 89.5 (p < 0.0001) |
| Coronary artery bypass graft | 17 | 1 | 94.1 (p < 0.0001) |
| ACVE | 105 | 11 | 89.5 (p < 0.0001) |